Market Overview

Medtronic Completes Enrollment in Landmark Study of IN.PACT Drug-Eluting Balloon in Peripheral Artery Disease

Share:
Related MDT
Following Intuitive Surgical's Solid Q2, Citi Asks What's Next
Medtronic Gets First-Ever FDA Approval For Cement-Augmented Pedicle Screws
Finding Some Of The Best-Quality Dividend Growth Stocks Using The Piotroski F Score (Seeking Alpha)

Committed to researching treatments for peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that patient enrollment in a landmark study of its IN.PACT Amphirion drug-eluting balloon is complete, with initial results expected in 2013.

The largest randomized controlled trial of its kind, IN.PACT DEEP is designed to assess the safety and efficacy of the IN.PACT Amphirion drug-eluting balloon as a treatment for one of the most severe forms of peripheral artery disease -- critical limb ischemia that occurs below the knee.

Posted-In: News FDA

 

Related Articles (MDT)

View Comments and Join the Discussion!